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Abstract
Importance—Despite lack of evidence of their utility, biomarkers of ovarian reserve are being 
promoted as potential markers of reproductive potential or “fertility tests.”
Objective—To determine the extent to which biomarkers of ovarian reserve are associated with 
reproductive potential among late-reproductive age women.
Design, Setting, and Participants—Prospective, time-to-pregnancy cohort study (2008-
March 2016) of women (N=981) 30–44 years of age without a history of infertility who had been 
trying to conceive for 3 months or less were recruited from the community in the Raleigh-Durham 
area.
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Exposures—Early follicular phase serum level of antimüllerian hormone (AMH), follicle 
stimulating hormone (FSH), and inhibin B, and urinary level of FSH.
Main Outcomes and Measures—The primary outcomes were the cumulative probability of 
conception by 6 and 12 cycles of attempt and relative fecundability, the probability of conception 
in a given menstrual cycle. Conception was defined as a positive pregnancy test.
Results—750 women (33.3[3.2] years of age; 77% white; 36% overweight or obese), provided a 
blood and urine sample and were included in the analysis. After adjusting for age, body mass 
index, race, current smoking status and recent hormonal contraceptive use, women with low AMH 
values (<0.7ng/ml, N=84) did not have a significantly different predicted probability of conceiving 
by 6 cycles of attempt (65%; 95% Confidence Interval (CI): 50–75%) compared to women 
(N=579) with normal values (62%; 95% CI: 57–66%) nor by 12 cycles of attempt (84%; 95% CI: 
70–91% versus 75%; 95% CI: 70–79%, respectively). Women with high serum FSH values 
(>10mIU/ml, N=83) did not have a significantly different predicted probability of conceiving after 
6 cycles of attempt (63%; 95% CI: 50–73%) compared to women (N=654) with normal values 
(62%; 95% CI: 57–66%) nor after 12 cycles of attempt (82%; 95% CI: 70–89 versus 75%; 95% 
CI: 70–78%). Women with high urinary FSH values (>11.5mIU/mgcr, N=69) did not have a 
significantly different predicted probability of conceiving after 6 cycles of attempt (61%; 95% CI: 
46–74%) compared to women (N=660) with normal values (62%; 95% CI: 58–66%) nor after 12 
cycles of attempt (70%; 95% CI: 54–80% versus 76%; 95% CI: 72–80%). Inhibin b levels 
(N=737) were not associated with the probability of conceiving in a given cycle (Hazard Ratio 
[per 1pg/ml increase] = 0.999; 95% CI: 0.997–1.001).
Conclusions—Among women age 30–44 years of age without a history of infertility, who had 
been trying to conceive for 3 months or less, biomarkers indicating diminished ovarian reserve, 
compared to normal ovarian reserve, were not associated with reduced fertility. These findings do 
not support the use of urinary or blood FSH tests or AMH levels to assess natural fertility for 
women with these characteristics.
INTRODUCTION
Women are delaying their attempts to conceive to older ages.1 As a woman ages, her oocyte 
and follicular pool declines.2 As the oocyte and follicular pool declines, granulosa cells 
secrete less inhibin B and antimüllerian hormone (AMH).3,4 Lower inhibin B levels lead to 
an earlier and more rapid rise in follicle stimulating hormone (FSH) during the follicular 
phase.5 Collectively, AMH and early follicular phase FSH and inhibin B have been referred 
to as biomarkers of ovarian reserve.
The ability of these biomarkers to predict reproductive potential is uncertain. AMH has been 
associated with time to menopause in a number of cohorts.6,7 Among women with infertility 
undergoing controlled ovarian hyperstimulation for in vitro fertilization (IVF), AMH is an 
excellent predictor of oocyte yield.8 Studies on the ability of these biomarkers to predict 
those women who will conceive with IVF have had inconsistent findings.9–11 Despite lack 
of evidence of their utility, biomarkers of ovarian reserve are being used as markers of 
reproductive potential or “fertility tests.” Home fertility tests based on day 3 urinary FSH 
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levels are commercially available. Additionally, clinicians use these tests, when counseling 
about elective oocyte cryopreservation.
The objective of this study was to determine the extent to which biomarkers of ovarian 
reserve (early follicular phase serum AMH, serum FSH, serum inhibin B, and urinary FSH) 
were associated with reproductive potential, as measured by the probability of conceiving 
naturally, in an older reproductive-age cohort of women recruited from the community. It 
was hypothesized that women with biomarker values suggesting diminished ovarian reserve 
would have a lower probability of conceiving in a given cycle (fecundability), by 6 cycles, 
and by 12 cycles of trying to conceive.
Methods
A prospective, time-to-pregnancy cohort study was conducted from April 2008 to March 
2016. Women were eligible to participate if they were between 30 and 44 years of age, had 
been attempting to conceive for 3 or fewer months, and were cohabitating with a male 
partner. Women were excluded if they had known fertility problems (history of sterilization, 
diagnosis of polycystic ovarian syndrome (PCOS), previous or current use of fertility 
treatments, known tubal blockage, surgically diagnosed endometriosis) or a partner with a 
history of infertility. Women who were currently breastfeeding or had used injectable 
hormonal contraception in the preceding year were also excluded. This study was approved 
by the Institutional Review Board of the University of North Carolina; all participants 
provided written consent.
Women were recruited through flyers in the community, radio and print ads, informational 
letters, and mass emails. They were screened for eligibility over the phone using a 
standardized questionnaire. Women, who met eligibility criteria, completed a questionnaire 
including demographics and information on factors potentially related to fertility. To 
characterize the study population, this questionnaire included a question about race. Women 
self-selected their race from categories provided. Women were instructed to contact the 
study coordinator with their subsequent menses. They were scheduled for a study visit on 
cycle day 2, 3, or 4 of their menstrual cycle. Women were mailed a urine collection kit and 
instructed to collect a first-morning urine sample on the day of their study visit. At that visit, 
a blood sample and urine sample (if not collected at home) was obtained from the 
participant. Women were provided with home urine pregnancy tests (sensitivity: 20 mIU 
HCG/ml). For the first 3 years of the study, women were instructed to perform the pregnancy 
test with missed menses; subsequently women were instructed to test starting on menstrual 
cycle day 28 and every 3 days thereafter.
While attempting to conceive, women completed a daily diary in which they recorded 
bleeding, intercourse, medications, and results of pregnancy tests. Women completed these 
diaries for up to 4 months and then subsequently completed monthly questionnaires. Initial 
versions of the questionnaires were on paper, and later versions were web-based. Women 
were instructed to contact study personnel if they tested positive for pregnancy. They were 
provided a free pregnancy ultrasound between 6 and 8 weeks gestation to encourage 
communication of results. Women were initially followed for up to 6 months, but the 
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protocol was subsequently modified in March 2010 to follow all women for up to 12 months 
of pregnancy attempt. They were withdrawn from the study at initiation of fertility 
medication, upon request (most commonly because they were moving or stopped trying to 
conceive), or when lost to follow up.
Serum Analysis
Serum samples were stored at -30°C until analysis. Samples were shipped frozen in a single 
batch to the University of Southern California Reproductive Endocrinology Laboratory. 
There they were assayed using sensitive and specific assays for FSH (Immulite analyzer, 
Siemens, Deerfield, IL), inhibin B (ELISA, Ansh Labs, Webster, TX), and AMH 
(Ultrasensitive AMH ELISA, Ansh, lower limit of detection 0.078 ng/ml). Interassay 
coefficients of variation ranged from and 4–5% for FSH, 5–8% for inhibin B, and 9–11% for 
AMH.
Urine Analysis
Urine was stored and shipped frozen to the National Institute for Occupational Safety and 
Health Reproductive Endocrinology Laboratory. There they were assayed for FSH and 
creatinine as described previously.12 To adjust for urine flow rate, urinary FSH values were 
divided by the respective creatinine concentration. Results are presented as mIU of FSH per 
mg of creatinine (mIU/mgcr). Intra-assay coefficients of variation were 3.5% for FSH and 
1.5% for creatinine.
Statistical Analysis
The primary outcome measures for the study were the cumulative probability of conception 
by 6 menstrual cycles, by 12 menstrual cycles, and relative fecundability. There were no 
secondary outcomes, but planned exploratory analyses examined associations between levels 
of AMH and the primary outcomes among age subgroups and between parity subgroups.
The biomarkers of ovarian reserve were considered as categorical variables where informed 
choices for cut-points were available. It was hypothesized that the relationship between 
AMH and fertility would be non-linear. After exploring clinical AMH cut off values of 
0.4ng/ml, 0.7ng/ml, and 1.0ng/ml, the middle cut-off value of 0.7ng/ml was selected based 
on previous research.13 The 90th percentile was selected as the upper level AMH cut-off 
value (8.5 ng/ml). The clinical value of 10mIU/ml was selected a priori as the serum FSH 
cut-off value.14 For urine, the corresponding FSH value is 11.5 mIU/mg creatinine, as 
documented previously.13 Inhibin B was modeled as a continuous variable, as no clinical 
cut-off values were available.
Non-parametric bivariate analyses were used to compare median biomarker levels by 
participant characteristics. Because women did not all enter at the same point during their 
attempts to conceive and some women withdrew, started fertility medications, or were lost to 
follow up, the cohort was analyzed using a discrete-time Cox proportional hazards model. 
Time was menstrual cycles at risk for pregnancy (pregnancy attempt cycle). Pregnancy 
attempt cycle was determined from the time a woman started trying to conceive, not from 
the time of enrollment. Attempt cycle at enrollment was defined by the pregnancy attempt 
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cycle (usually cycle 1, 2, or 3) in which the woman began participation (completed diaries or 
baseline questionnaire). Women were censored at the time they withdrew, started fertility 
medications, or were lost to follow up. Thus, cycles from enrollment to censoring were 
included in the analysis. As time in these models is measured by menstrual cycles (and not 
chronologic time) the hazard ratios (HRs) are commonly referred to as fecundability ratios, 
which are the relative probability of pregnancy in a given cycle for the exposed relative to 
the reference group. In such models an HR less than one suggests reduced fecundability in 
the exposed (or non-referent) group.
The Cox proportional hazard models were then used to calculate the cumulative probability 
of conceiving (with 95% confidence intervals) at 6 and 12 cycles of attempt for each 
biomarker level. All models adjusted for age (3 categories: <35, 35–37, 38–44)15, body mass 
index (4 categories: <18.5, 18.5–24.9, 25–29.9, ≥30 kg/m2)16, race (White: yes/no), current 
smoking status (yes/no), and hormonal contraceptive use in the preceding year (yes/no). 
Adjusted Kaplan Meier curves with 95% confidence intervals were also constructed. The 
predicted probabilities and Kaplan Meier curves were calculated by setting all of the 
covariates to the mean of the cohort. Planned subgroup analyses were conducted by age and 
parity. To test for interaction by age and parity, a likelihood ratio test was used to compare 
the fit for the model without the interaction term to the model including the interaction term. 
In addition, post hoc sensitivity analyses were conducted by creating additional Cox models 
to assess different cut-off values and to evaluate potential biases.
A sample size of 750 women was selected based on an a priori power analysis. A 10% loss 
to follow-up, 70% pregnancy rate in the control group, a 57% pregnancy rate by 6 months in 
the diminished ovarian reserve group, and 80% power at a type I error rate of 0.05 was 
conservatively presumed based on the pilot study. 13 SAS (version 9.3) and R (version 3.3.0) 
were used for statistical analysis. All testing was two-sided. P-values less than 0.05 were 
considered statistically significant; there was no adjustment for multiple comparisons.
Results
Study flow is presented in Figure 1; 981 women were enrolled in the Time to Conceive 
study; 770 of these women had a study visit; 750 women would ultimately be included in the 
analysis. Of these, 37 (5%) withdrew, 47 (6%) started fertility medications, 56 (7%) were 
lost to follow up, 487 (65%) conceived, and 123 (17%) completed the study but did not 
conceive. Of the analyzed cohort, 69% of participants were 30 to 34 years of age; 19% were 
between 35 and 37 years of age, and 12% were 38 years or older. Most participants were 
White (77%) and highly educated (62% with a graduate degree). The majority of women 
had a normal BMI (62%), while 3% were underweight and 36% were overweight or obese. 
Cox analysis showed that the probability of conception was 65% by 6 cycles of attempt and 
77% by 12 cycles of attempt. Fecundability over each attempt cycle is presented in Table 1.
The distributional statistics for the observed biomarkers of ovarian reserve are as follows. 
Serum AMH, inhibin B, and FSH values were missing for 13 (2%) of study participants, and 
were excluded from AMH, inhibin b, and FSH analyses accordingly. Urinary FSH values 
were missing for 21 (3%) of the participants and were excluded from the analyses of urinary 
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FSH. Each participant had at least one biomarker value. Eleven percent of women had an 
AMH value of 0.7ng/ml or less; 10% (by design) had an AMH value of 8.5ng/ml or higher. 
11% had a serum FSH value of 10mIU/ml or higher; 9% had a urine creatinine corrected 
FSH value of 11.5 mIU/mg creatinine or higher. The median value for inhibin B was 70 
pg/ml (Interquartile range: 38–102).
Table 2 presents the unadjusted median values of each biomarker (with interquartile range) 
by participant characteristics. As expected, AMH levels decreased and urinary FSH values 
increased with female age. Compared to non-obese women, obese women had lower AMH 
(p=0.007) and inhibin B values (p=0.005). Biomarker values did not significantly differ by 
education level, race, smoking status, hormonal contraceptive use in the preceding year, or 
cycle of pregnancy attempt in which the study participant was enrolled. Women who had 
previously been pregnant had significantly lower AMH values and higher urinary FSH 
values in this unadjusted analysis.
AMH values were not statistically different across years of sample collection (Kruksal-
Wallis test, p=0.83) suggesting that AMH levels, as measured using the Ansh assay, are 
stable over prolonged storage at −30°C. A subset (N=99) of samples were analyzed for 
AMH using the Diagnostic Systems Laboratory (DSL) Assay, Gen II Assay (Beckman 
Coulter), and Ansh Assay. There was high pairwise correlation between assay values 
(Pearson’s r=0.96–0.97, p<0.001).
Results for Primary Outcomes
The predicted probability of conceiving by 6 cycles or 12 cycles of attempt, as calculated 
from the Cox models, was not lower for women with low AMH or high FSH, as had been 
hypothesized (Table 2). Women with low AMH values (<0.7ng/ml) did not have a 
significantly different cumulative probability of conceiving by 6 cycles of attempt (65%; 
95% Confidence Interval (CI): 50–75%) compared to women with normal values (62%; 95% 
CI: 57–66%) nor by 12 cycles of attempt (84%; 95% CI: 70–91% versus 75%; 95% CI: 70–
79%, respectively). Women with high serum FSH values (>10mIU/ml) did not have a 
significantly different cumulative probability of conceiving after 6 cycles of attempt (63%; 
95% CI: 50–73%) compared to women with normal values (62%; 95% CI: 57–66%) nor 
after 12 cycles of attempt (82%; 95% CI: 70–89% versus 75%; 95% CI: 70–78%). Kaplan 
Meier curves, comparing adjusted cumulative probabilities of conception by categories of 
ovarian reserve biomarkers, are presented in Figures 2, 3, and 4. Though the curves suggest 
longer times to pregnancy in women with higher AMH values and for those with lower FSH 
values, confidence intervals are overlapping for both biomarkers. High and normal urinary 
FSH value curves are almost indistinguishable from one another.
Relative fecundability (HRs) according to biomarker values as calculated from the discrete-
time Cox models are presented in Table 3. Women with low AMH values or high serum 
FSH values, which suggest diminished ovarian reserve, did not have reduced fecundability, 
as had been hypothesized. Inhibin b levels (N=737) were also not associated with the 
probability of conceiving in a given cycle (Hazard Ratio [per 1pg/ml increase] = 0.999; 95% 
CI: 0.997–1.001).
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Results of Secondary Analyses
Planned subgroup analyses by age and parity were conducted (Table 4). In every age group, 
low AMH was not associated with diminished fecundability. Point estimates suggested 
higher fecundability among women with low AMH at any age. The relationship between 
high AMH and fecundability appeared to differ by a woman’s age. In younger women, high 
AMH suggested reduced fecundability. However, among older women, high AMH 
suggested higher fecundability. Though these point estimates differed, the confidence 
intervals overlap, and the age-interaction was not found to be statistically significant 
(p=0.35). Subsequent subgroup analysis by pregnancy history also did not reveal significant 
effect modification by pregnancy history (Table 4).
In sensitivity analyses different cut-off values for AMH were examined. Women with AMH 
values ≤0.4ng/ml had a HR of 1.40 (95%CI: 0.95–2.07) compared to women with AMH 
values between 0.4 ng/ml and 5.0 ng/ml. Women with AMH values ≤1.0 ng/ml had a HR of 
1.16 (95% CI: 0.89–1.50) compared to women with AMH values between 1.0 ng/ml and 5.0 
ng/ml. Also after adjusting for hormonal contraception use in the preceding 3 months 
(information available on 552 women) the HRs were further from the null, but remained 
statistically non-significant (for low AMH HR 1.30; 95% CI: 0.92–1.86 and for high AMH 
HR 0.75; 95% CI: 0.51–1.10). Restricting the analysis to women who entered into the study 
at cycle 1, 2, or 3 of attempt did not change the findings.
Discussion
In this cohort of older reproductive-age women attempting to conceive naturally, biomarkers 
of diminished ovarian reserve (low AMH or high FSH) were not associated with reduced 
fecundability, or a lower cumulative probability of conceiving by 6 or 12 cycles of 
pregnancy attempt. Early follicular phase inhibin B levels were also not associated with 
fertility outcomes.
In an earlier, small pilot, Steiner et al. found that low AMH (<0.7 ng/ml) as measured using 
the DSL assay was associated with a 60% reduction in the day-specific probability of 
conception.13 Those findings are different from current findings in this larger cohort - most 
likely due to sample size. Also, the pilot used a day-specific probability analysis. This 
method utilizes information on intercourse patterns around the time of ovulation that relied 
on a calendar method that could have led to misclassification. Second, a different AMH 
assay was used. There is some evidence that the Ansh assay provides higher values 
compared to other assays. 17 However, a sensitivity analyses with the higher (AMH≤1.0 
ng/ml) and lower cut-off values (AMH≤0.4 ng/ml) was conducted, and there was still no 
evidence of reduced fecundability in either of the “low AMH” groups.
Three other publications examined AMH and fecundability, in women attempting to 
conceive naturally, and none reported significant associations.18–20 In a prospective study of 
186 Danish women, Hagen et al. found that fecundability was not significantly reduced in 
women with low AMH (≤10pmol/L, approximately ≤1.4 ng/ml) compared to women with 
normal AMH levels (HR 0.81, 95% CI 0.44–1.40).18 The Hagen cohort included women in 
their mid-twenties and had a smaller sample size (N=186). A secondary analysis of the 
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EAGER study, which was a randomized clinical trial of aspirin for women (average age 
28.7±4.8 years) with a prior pregnancy loss, found no statistically significant association 
between low AMH and fecundability using the Gen II assay with a cut-off value of 1.0 
ng/ml (HR 1.13, 95% CI: 0.85–1.49).19
Given that prior studies were small or based on secondary analyses, the finding in the 
current large, well designed study that women with diminished ovarian reserve did not have 
reduced fertility was surprising and contrary to the hypothesis. Although both ovarian 
reserve and fertility decline with chronologic age when looking at cross-sectional data, there 
may be little association between a given woman’s ovarian reserve and factors that affect her 
fertility, such as egg quality. AMH and FSH levels may, however, affect follicular 
recruitment in those with diminished ovarian reserve. It is possible that low AMH allows for 
a greater proportion of the remaining primordial follicle pool to activate and become 
growing follicles. Additionally, high FSH seen in women with low reserve could lead to 
“superovulation” with multi-follicular ovulation, increasing the odds of pregnancy. It has 
previously been shown that women of advanced maternal age are at higher risk of dizygotic 
twins.21
It was hypothesized that younger women with diminished ovarian reserve might not have 
decreased fertility, but that older women would. However, the exploratory subgroup analysis 
did not support this. Neither the younger (30–35 years of age) nor older women with 
diminished ovarian reserve (as measured by AMH) displayed reduced fecundability. 
However, high AMH was non-significantly associated with reduced fecundability in the 
younger women and increased fecundability in the older women. Hagen et al. similarly 
found that young women with high AMH levels had reduced fecundability (HR 0.62; 95% 
CI: 0.39–0.99).18 AMH is not only a marker of ovarian reserve, but also a potential marker 
for polycystic ovarian syndrome. While the appropriate AMH cut-off value for PCOS is 
debated, multiple studies have shown that AMH is elevated in women with PCOS.17,22 In 
the younger women, high AMH values may suggest undiagnosed polycystic ovarian 
syndrome. High AMH may inhibit follicle sensitivity to FSH and subsequent follicular 
recruitment.23 In the older women, high AMH may simply reflect higher than normal 
ovarian reserve. Further study of women with high AMH across various age groups and over 
time is warranted.
This study has several strengths. First, it was specifically designed to address the important 
public health question: Is diminished ovarian reserve a cause of infertility in late-
reproductive-age women? Second, the sample size is large enough to detect even relatively 
small effects. Third, its prospective design allows for biomarker testing at the appropriate 
time and inclusion of participants with the full range of natural fertility. Fourth, most women 
were enrolled during their first three menstrual cycles of attempting to conceive. Enrolling 
women later selects a less fertile cohort, as 50% of women will likely conceive within the 
first 3 cycles.24 Fifth, the age range studied (30–44 years) focuses on women at risk of 
diminished ovarian reserve. Sixth, the study protocol standardized the outcome measure 
(whether or not a woman conceived in any given menstrual cycle). This was done by 
providing women free pregnancy tests and instructing them on when to test for pregnancy. 
Thus, the sensitivity of the test was the same for all, and the set timing of testing minimized 
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the potential for differential identification of pregnancies. Seventh, the ovarian reserve 
markers evaluated include urinary FSH, which is used in the commercially available test kits 
marketed for women to assess their natural fertility. Thus, the findings relate directly to the 
usefulness of such tests. Eighth, biomarkers were measured in all study participants during 
the early follicular phase, minimizing potential variation in biomarkers due to the phase of 
the menstrual cycle.
This study has several limitations. First, conception, not live birth, was the primary outcome. 
Fecundity, the capacity to reproduce, is comprised of both the ability to conceive and to 
carry a fetus to viability. Diminished ovarian reserve could affect fecundity by increasing the 
risk of miscarriage- perhaps through an effect on egg quality. Prior studies to date have 
failed to show such an association.25,26 Second, not all women remained in the study for 12 
cycles of attempt. This was anticipated, given the older reproductive-age cohort. Current 
recommendations advise women over the age of 35 to obtain an infertility evaluation after 6 
months of attempt. The median attempt cycle at which women started infertility treatment in 
the study was 8 cycles. For this reason conception by 6 cycles of attempt was calculated and 
Cox models, which allow participants who initiate fertility medications to contribute time to 
the analysis until they are censored for their fertility medication use, were constructed. 
Third, ovulation was not assessed. This information would have allowed us to evaluate the 
strictest definition of fecundability (the probability of conceiving in a given ovulatory 
menstrual cycle). Fourth, male partners did not provide a semen sample for analysis. 
However, there is no reason to think that women with diminished ovarian reserve would be 
more or less likely to be partnered with a male with abnormal semen parameters. Fifth, not 
all women were enrolled in their first, second, or third cycle of attempt; however, when the 
<10% of women who entered after their third cycle of attempt were excluded, the findings 
did not differ. Sixth, while various AMH cut-off values were explored, the study was not 
powered to look at very low (0.1ng/ml or lower) AMH values, which reflect diminished 
ovarian reserve more consistent with the late perimenopause transition. It is possible that in 
such advanced stages, fecundability may be affected, especially if it results in frequent 
anovulation.
Conclusions
Among women age 30–44 years of age without a history of infertility, who had been trying 
to conceive for 3 months or less, biomarkers indicating diminished ovarian reserve, 
compared to normal ovarian reserve, were not associated with reduced fertility. These 
findings do not support the use of urinary or blood FSH tests or AMH levels to assess 
natural fertility for women with these characteristics.
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KEY POINTS
Question
Is diminished ovarian reserve, as measured by low antimüllerian hormone (AMH) 
associated with infertility among late-reproductive age women?
Findings
In this time-to-pregnancy cohort study of women 30–44 years of age without a history of 
infertility, women with a low AMH value had an 84% predicted cumulative probability of 
conception by 12 cycles of pregnancy attempt compared to 75% in women with a normal 
AMH value, a non-significant difference.
Meaning
For women attempting to conceive naturally, diminished ovarian reserve was not 
associated with infertility; women should be cautioned against using AMH levels to 
assess their current fertility.
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Figure 1. 
Study flow chart of participants in the cohort
*Number screened and reasons and numbers for exclusions are not available
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Figure 2. 
Adjusted Kaplan Meier Curves for time to pregnancy with 95% confidence intervals by 
AMH. Model adjusted for age, body mass index, race, current smoking status, history of 
prior pregnancy, and hormonal contraceptive use in the preceding year. The number of 
women at risk during each cycle of attempt are provided in supplemental table 1. The 
median (interquartile range) number of cycles each woman contributed was 4 cycles (2–6).
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Figure 3. 
Adjusted Kaplan Meier Curves for time to pregnancy with 95% confidence intervals by 
early follicular phase serum FSH. Model adjusted for age, body mass index, race, current 
smoking status, history of prior pregnancy, and hormonal contraceptive use in the preceding 
year. The number of women at risk during each cycle of attempt are provided in 
supplemental table 1. The median (interquartile range) number of cycles each woman 
contributed was 4 cycles (2–6).
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Figure 4. 
Adjusted Kaplan Meier Curves for time to pregnancy with 95% confidence intervals by 
early follicular phase, creatinine-corrected, urinary FSH. Model adjusted for age, body mass 
index, race, current smoking status, history of prior pregnancy, and hormonal contraceptive 
use in the preceding year. The number of women at risk during each cycle of attempt are 
provided in supplemental table 1. The median (interquartile range) number of cycles each 
woman contributed was 4 cycles (2–6).
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Table 1
Flow of participants throughout study, which shows the attempt cycle participants entered the study, the 
number that conceived in each cycle (fecundability), and the number of women, who were censored 
(withdrew, started fertility medications, lost-to-follow up, or completed the study) in each cycle. Only data 
from the first 12 attempt cycles are presented.
Cycle of pregnancy attempt Number entered study Women at risk* Number (%) conceived # Censored in this cycle
1 388 388 54 (14%) 9
2 191 516 84 (16%) 10
3 105 527 103 (20%) 22
4 39 441 77 (17%) 15
5 12 361 49 (14%) 24
6 4 292 47 (16%) 21
7 1 225 25 (11%) 29
8 0 171 16 (9%) 24
9 2 133 12 (9%) 17
10 0 104 3 (3%) 16
11 0 85 5 (6%) 9
12 1 72 2 (3%) 12
*
Includes all the women that entered into the study during this attempt cycle or entered in a preceding cycle and did not conceive and were not 
censored (for starting a fertility medication, withdrawal, or lost to follow up).
Women at risk in cycleX= number entered study at cyclex + number at risk in cyclex−1 − (number conceivedx−1+number censoredx−1).
For example, number at risk in cycle 3=105+516−(84+10)=527.
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